Home Bratislava Medical Journal 2024 Bratislava Medical Journal Vol.125, No.3, p. 149–152, 2024

Journal info


 


Published Monthly, in English
Founded: 1919
ISSN 0006-9248
(E)ISSN 1336-0345

Impact factor 1.564

 

Aims and Scope
Editorial Info
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.

Bratislava Medical Journal Vol.125, No.3, p. 149–152, 2024

Title: Robotic stereotactic radiosurgery with CyberKnife – brain metastases and fibrinolysis
Author: Veselin POPOV, Vasko GRAKLANOV, Snezhana STOENCHEVA, Zhanet GRUDEVA-POPOVA
Abstract: OBJECTIVES: Deviations in haemostasis are found in about 50 % of patients with cancer and up to 90% of those with metastatic disease. Many studies investigate the dynamics of the processes of coagulation and fibrinolysis and their role as a predictor of therapeutic response, early relapse, or metastasis risk.
BACKGROUND: To investigate the serum levels of urokinase plasminogen activator (uPA) in patients with brain metastases treated with robotic stereotactic radiosurgery (SRS) with CyberKnife.
MATERIAL AND METHODS: Serum levels of urokinase plasminogen activator (uPA) were measured in 66 patients with solid tumours, divided into two groups, with oligometastatic disease and brain metastases. In this prospective longitudinal study, the serum levels of uPA were measured before starting the therapy and at the first, third, and sixth months after patients were irradiated with the CyberKnife system.
RESULTS: Analysis of serum uPA levels in the post-treatment period showed a statistically significant decrease between the baseline and the 6 months post-treatment time point in both patient groups. The baseline value of serum uPA in the group with lung cancer decreased by 62.7 %, and in the group with other types of cancer – by 60 %. Despite the significant reduction of serum uPA levels 6 months after the treatment, the levels remained significantly higher in both groups than in healthy controls.
CONCLUSION: Ongoing research on uPA and cancer will enrich our knowledge and expand the possibilities for clinical utilization of the marker in the oncology setting (Tab. 2, Ref. 18).
Keywords: solid tumours, urokinase plasminogen activator, brain metastases, robotic stereotactic radiosurgery, CyberKnife
Published online: 27-Dec-2023
Year: 2024, Volume: 125, Issue: 3 Page From: 149, Page To: 152
doi:10.4149/BLL_2023_139


download file


© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.